1. Home
  2. AYTU vs FRSX Comparison

AYTU vs FRSX Comparison

Compare AYTU & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • FRSX
  • Stock Information
  • Founded
  • AYTU N/A
  • FRSX N/A
  • Country
  • AYTU United States
  • FRSX Israel
  • Employees
  • AYTU N/A
  • FRSX N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • AYTU Health Care
  • FRSX Technology
  • Exchange
  • AYTU Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • AYTU 9.6M
  • FRSX 8.6M
  • IPO Year
  • AYTU N/A
  • FRSX 2017
  • Fundamental
  • Price
  • AYTU $2.40
  • FRSX $0.37
  • Analyst Decision
  • AYTU Strong Buy
  • FRSX
  • Analyst Count
  • AYTU 2
  • FRSX 0
  • Target Price
  • AYTU $10.00
  • FRSX N/A
  • AVG Volume (30 Days)
  • AYTU 151.8K
  • FRSX 827.8K
  • Earning Date
  • AYTU 09-25-2025
  • FRSX 08-12-2025
  • Dividend Yield
  • AYTU N/A
  • FRSX N/A
  • EPS Growth
  • AYTU N/A
  • FRSX N/A
  • EPS
  • AYTU N/A
  • FRSX N/A
  • Revenue
  • AYTU $81,659,000.00
  • FRSX $436,000.00
  • Revenue This Year
  • AYTU N/A
  • FRSX N/A
  • Revenue Next Year
  • AYTU $1.05
  • FRSX N/A
  • P/E Ratio
  • AYTU $13.14
  • FRSX N/A
  • Revenue Growth
  • AYTU 0.41
  • FRSX N/A
  • 52 Week Low
  • AYTU $0.95
  • FRSX $0.36
  • 52 Week High
  • AYTU $2.85
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 53.72
  • FRSX 28.94
  • Support Level
  • AYTU $2.55
  • FRSX $0.40
  • Resistance Level
  • AYTU $2.72
  • FRSX $0.46
  • Average True Range (ATR)
  • AYTU 0.14
  • FRSX 0.04
  • MACD
  • AYTU -0.02
  • FRSX -0.01
  • Stochastic Oscillator
  • AYTU 46.67
  • FRSX 7.23

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: